As a part of a broader investment round, Beyond Air’s subsidiary NeuroNOS has received an initial equity financing of $2m from private investors, aimed at expediting the preclinical development of its small-molecule drug for paediatrics with autism.
A collaborative effort between Duke-NUS Medical School and the National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine) has led to the launch of the joint research centre named Systems Metabolomics Centre (SysMeC), aimed at metabolomics research.
The US Food and Drug Administration (FDA) has granted approval for Novartis’ Fabhalta (iptacopan), intended to minimise proteinuria in the adult population with C3 glomerulopathy (C3G).
Contract development and manufacturing organisation (CDMO) Porton Advanced has announced a partnership with Eureka Therapeutics to expedite the worldwide clinical development of T-cell therapies.
Contract development and manufacturing organisation (CDMO) Delpharm has announced plans to invest over C$200m ($140m) to modernise its Boucherville facility in Canada.
The US Food and Drug Administration (FDA) has granted orphan drug designation for Korro Bio’s KRRO-110 to treat alpha-1 antitrypsin deficiency (AATD).
The US Food and Drug Administration (FDA) has granted clearance for PDS Biotechnology's investigational new drug (IND) application to assess Versamune MUC1 plus PDS01ADC for the treatment of unresectable, metastatic colorectal carcinoma (mCRC).
LGM Pharma has announced more than $6m investment to expand its manufacturing facility in Rosenberg in the US state of Texas.
Aprea Therapeutics has signed a material transfer agreement (MTA) with MD Anderson Cancer Center to explore APR-1051 for head and neck squamous cell carcinoma (HNSCC).
Swiss biopharmaceutical company Relief Therapeutics has confirmed the termination of discussions with the US-based clinical-stage biotechnology company Renexxion regarding a potential merger.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.